MNK.N
Latest Trade
3.57USDChange
-0.12(-3.25%)Volume
631,383Today's Range
-
3.8452 Week Range
-
27.30As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 3.69 |
|---|---|
Open | 3.71 |
Volume | 631,383 |
3M AVG Volume | 178.83 |
Today's High | 3.84 |
Today's Low | 3.52 |
52 Week High | 27.30 |
52 Week Low | 1.43 |
Shares Out (MIL) | 84.09 |
Market Cap (MIL) | 282.55 |
Forward P/E | 0.39 |
Dividend (Yield %) | -- |
Mallinckrodt Announces Plans To Update Its Incentive Compensation Clawback Policy And Create Opioid Report
Mallinckrodt - Issuers, Exchanging Holders Entered Into Amendment To Exchange Agreement On Nov 27
Mallinckrodt Reports Positive Phase 3 Results From CONFIRM Study Of Terlipressin
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.
Industry
Major Drugs
Executive Leadership
Angus Charles Russell
Independent Non-Executive Chairman of the Board
Mark C. Trudeau
President, Chief Executive Officer, Director
Bryan M. Reasons
Chief Financial Officer
Ian J. Watkins
Chief Human Resource Officer
Steven Romano
Executive Vice President, Chief Scientific Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 0.09 |
Price To Book (MRQ) | 0.09 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 187.14 |
LT Debt To Equity (MRQ) | 163.90 |
Return on Investment (TTM) | -31.28 |
Return on Equity (TTM) | -28.21 |
Mallinckrodt Plc said on Tuesday it has received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker's lawsuit against the U.S. Department of Health and Human Services (HHS).
Endo International Plc, Johnson & Johnson and other drugmakers that face litigation over the opioid crisis are exploring a way to settle the cases by participating in Purdue Pharma LP's bankruptcy, the Wall Street Journal reported, citing internal documents and a person...
Mallinckrodt Plc <MNK.N> shares surged more than 50% on Tuesday after it agreed to sell its contract manufacturing unit to reduce debt and its chief executive officer raised hopes that the company could reach a global settlement to resolve all opioid litigation.
Drugmaker Mallinckrodt Plc said on Tuesday it would sell its unit BioVectra Inc to private equity firm H.I.G. Capital for up to $250 million.
Mallinckrodt plc said on Friday it had agreed to pay $24 million in cash to two counties in Ohio, to settle lawsuits related to an ongoing multidistrict opioid litigation in the United States.
Drugmaker Mallinckrodt plc said on Friday it will pay $24 million in cash to two counties in Ohio, to settle lawsuits in connection with an ongoing multidistrict opioid litigation in the United States.
Mallinckrodt Plc on Thursday downplayed a media report that the company had hired restructuring firms and may choose to seek bankruptcy protection.
Mallinckrodt Plc <MNK.N> has hired restructuring firms and may choose to seek bankruptcy protection, Bloomberg reported on Wednesday, sending the drugmaker's shares down 40% in after-hours trading.
Shares of Mallinckrodt Plc <MNK.N> fell 12% on Tuesday after a U.S. Court of Appeals upheld a federal district court's decision to reject the drugmaker's patent infringement lawsuit against Praxair Inc's nitric oxide drug product delivery system.
Mallinckrodt Plc <MNK.N> suspended plans to spin off its specialty generics unit, citing opioid litigation uncertainties, and warned Acthar gel revenue was unlikely to exceed $1 billion this year, sending its shares down about 15% on Tuesday.
Mallinckrodt Plc said on Tuesday it has suspended plans to spin off its specialty generics business, citing uncertainties tied to the opioid litigation and current market conditions.
Mallinckrodt Plc on Wednesday said it had tentatively agreed to pay $15.4 million to resolve a U.S. Justice Department probe into how a drugmaker it now owns marketed an expensive treatment for a rare infant seizure disorder and multiple sclerosis.
Mallinckrodt Plc said on Wednesday it reached an agreement with the U.S. Department of Justice to resolve a government investigation into its subsidiary Questcor and expects to pay $15.4 million.
Mallinckrodt Plc said on Tuesday it would spin off its generic drugs business as a separate unit and keep constipation medicine Amitiza as part of its specialty branded drugs business, which will be renamed as Sonorant Therapeutics Plc.
Mallinckrodt Plc said on Tuesday it would spin-off its specialty generics unit and rename the remaining specialty branded drugs business to Sonorant Therapeutics Plc.
Mallinckrodt Plc filed a lawsuit against the U.S. Department of Health and Human Services and forecast an about 10% hit to annual net sales of Acthar gel following changes to Medicaid rebate calculations, sending its shares plunging as much as 34% on Tuesday.
Mallinckrodt Plc filed a lawsuit against the U.S. Department of Health and Human Services and forecast an about 10% hit to annual net sales of its gel used to treat multiple sclerosis symptoms following changes to Medicaid rebate calculations, sending shares plunging as...
The U.S. Justice Department has joined a pair of whistleblower lawsuits alleging a drugmaker now owned by Mallinckrodt Plc improperly promoted an expensive multiple sclerosis treatment and paid kickbacks to doctors who prescribed the drug.
The U.S. Food and Drug Administration has declined to approve an abuse-deterrent version of Mallinckrodt Plc's opioid painkiller Roxicodone, saying some parts of the company's application need further evaluation.
Mallinckrodt Plc said on Wednesday the U.S. Food and Drug Administration declined to approve an abuse-deterrent version of its opioid painkiller Roxicodone.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.